Effects of D-003, a new compound purified from sugarcane wax, on platelet aggregation in healthy volunteers: A randomised, double-blind clinical study

Clinical Drug Investigation

Volumn 23, Issue 2, 2003, Pages 107-118

  Arruzazabala, Maria De Lourdes ^a   Carbajal, Daisy ^a   Mas, Rosa ^a   Molina, Vivian ^a   Castaño, Gladys ^b   Gámez, Rafael ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^b Medical Surgical Research Center   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; COLLAGEN TYPE 1; D 003; PLACEBO;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INHIBITION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RACEMIC MIXTURE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

EID: 0037220697     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323020-00004     Document Type: Article

References (43)

1. Wu K. Recent advances in hemostatic risk factors and cardiovascular diseases. Fibrinolysis and Proteolysis 1997, 34
2. Murray CJL, López AD. Alternate projections of mortality and disability by cause 1990-2020: global burden disease study. Lancet 1997; 349: 1498-504
3. Brown MS, Goldstein JL. Heart attacks: gone with the century. Science 1996; 272: 629-30
4. Falk E, Fernández-Ortiz A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol 1995; 75: 1B-7B
5. Schafer A. Antiplatelet therapy. Am J Med 1996; 101: 199-209
6. Haller H. Endothelial function: general considerations. Drugs 1997; 53 Suppl. 1: 1-10
7. Luscher TF. Biology of the endothelium. Clin Cardiol 1997; 20 (11 Suppl. 2): II-3-II-10
8. Shah PK. Plaque disruption and coronary thrombosis: new insights into pathogenesis and prevention. Clin Cardiol 1997; 20 (11 Suppl. 2): II-38-II-44
9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
10. Cairns JA, Lewis DJ, Meade TW, et al. Antithrombotic agents in coronary artery disease. Chest 1995; 108 Suppl. 4: 380s-400s
11. Sherman D, Dyken M, Gent M, et al. Antithrombotic therapy for cerebrovascular disorders: an update. Chest 1995; 108 Suppl. 4: 444s-56s
12. Euroaspire Study group. European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569-82
13. Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J 1998; 19 Suppl A: A12-9
14. Hassan M, Amonkar M. Aspirin for primary and secondary prophylaxis of cardiovascular disease. Curr Ther Res Clin Exp 2001; 62: 676-90
15. Awiry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-8
16. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001; 119: 39S-63S
17. McTavish D, Faulds D, Goa KL. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990; 40: 238-59
18. Coukell AJ, Markham A. Clopidogrel. Drugs 1997; 54: 745-50
19. The CAPRIE Study Group. A randomized, blinded, trial of clopidogrel versus aspirin in patients at high risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-39
20. Coller BS, Peerch EI, Scudder LE, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thromboasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38
21. Tanemoto K, Kanaoka Y, Kuinose M. Assessment of antithrombotic agents using the platelet aggregation test. Curr Ther Res Clin Exp 2000; 61: 798-806
22. Gonzalez L, Marrero D, Laguna A, et al. (Laboratorios Dalmer SA). Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses. Republic of South Africa patent 98-2744. December 30, 1998
23. Molina V, Arruzazabala ML, Carbajal D, et al. Antithrombotic effects of D003. Pharmacol Res 2000; 42: 137-43
24. Molina V, Arruzazabala ML, Carbajal D, Mas R. D-003, a new compound with effects on arachidonic acid metabolites. Prostagl Leukotr Essent Fatty Acids 2002. In press
25. Mas R. Policosanol. Drugs of the Future 2000; 25: 569-86
26. Gámez R, Más R, Noa M, et al. Acute and subchronic oral toxicity of D-003 in rats. Toxicol Lett 2000; 118: 31-41
27. Gámez R, González JE, Rodeiro I, et al. In vivo genotoxic evaluation of D-003, a mixture of very long-chain aliphatic acids. J Med Food 2001; 4: 85-92
28. Gámez R, Rodeiro I, Fernández I, Acosta PC. A preliminary evaluation of the cytotoxic and genotoxic potential of D-003: a mixture of very long chain fatty acids. Teratog Carcinog Mutagen 2001. In press
29. Castaño G, Mas R, Fernández L, et al. Assessment of the effects of D-003, a new antiplatelet and lipid-lowering compound, in healthy volunteers. Drugs R&D 2002; 3: In press
30. Born G. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (L) 1962; 194: 927-30
31. Kawai T. Blood coagulation. 2nd ed. Tokyo: Igaku Shoin, 1973
32. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem 1981; 27: 838-41
33. Friedewald WT, Levy IR, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
34. O'Brien PC, Shampo MA. Statistical considerations for performing multiple tests in a single experiment: comparing two therapies with respect to several endpoints. Mayo Clin Proc 1988; 63: 1140-3
35. Emms H, Lewis GP. The roles of prostaglandin endoperoxides thromboxane A2 and adenosine diphosphate in collagen-induced aggregation in man and the rat. Br J Pharmacol 1986; 87: 109-15
36. Tohgi H, Konno S, Tamura K, et al. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 1992; 23: 1400-3
37. Gámez R, Mas R, Noa M, et al. Six-month toxicity study of oral administration of D-003 in Sprague Dawley rats. Drugs R&D. In press
38. Gámez R, Mendoza S, Mas R, et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res Clin Exp 2000; 61: 8-16
39. Mendoza S, Gámez R, Noa M, et al. The effects of D-003 and policosanol on the lipid profile and endothelemia cells in normocholesterolemic rabbits: a head to head comparison. Curr Ther Res Clin Exp 2001; 62: 209-20
40. Luoma PV. Gene activation, apohpoprotein A-I, high-density lipoprotein, atherosclerosis prevention and longevity. Pharmacol Toxicol 1997; 81: 57-64
41. Menéndez R, Más R, Marrero D. et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids [abstract]. Atherosclerosis 2000; 151: 131
42. Menéndez R, Mas R, Pérez Y, et al. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003. Can J Physiol Pharmacol. In press
43. Aviram M. Macrophages, LDL oxidation and atherosclerosis. In: Jacotot B, Mathé D, Fruchart JC, editors. Atherosclerosis XI International Congress; Excerpta Medica: series 1155. Singapore: Elsevier Science, 1998: 483-492